Statement of Organization, Functions and Delegations of Authority, 78259-78262 [2010-31383]
Download as PDF
Federal Register / Vol. 75, No. 240 / Wednesday, December 15, 2010 / Notices
Dated: December 9, 2010.
Leslie Kux,
Acting Assistant, Commissioner for Policy.
[FR Doc. 2010–31386 Filed 12–14–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–D–0616]
Draft Guidance for Industry on
Codevelopment of Two or More
Unmarketed Investigational Drugs for
Use in Combination; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Codevelopment of
Two or More Unmarketed
Investigational Drugs for Use in
Combination.’’ This guidance is
intended to assist sponsors in the
codevelopment of two or more novel
(not previously marketed) drugs to be
used in combination to treat a disease or
condition. This guidance provides
recommendations and advice on how to
address certain scientific and regulatory
issues that will arise during
codevelopment. The guidance is not
intended to apply to development of
fixed-dose combinations of already
marketed drugs or to development of a
single new investigational drug to be
used in combination with an approved
drug or drugs. The guidance is also not
intended to apply to vaccines, gene or
cellular therapies, blood products, or
medical devices.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by February 14,
2011.
SUMMARY:
Submit written requests for
single copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
hsrobinson on DSK69SOYB1PROD with NOTICES
ADDRESSES:
VerDate Mar<15>2010
19:10 Dec 14, 2010
Jkt 223001
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Colleen Locicero, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm 4216,
Silver Spring, MD 20993–0002, 301–
796–1114.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Codevelopment of Two or More
Unmarketed Investigational Drugs for
Use in Combination.’’ The guidance is
intended to assist sponsors interested in
developing two or more novel (not
previously marketed) drugs to be used
in combination. Recent scientific
advances have increased our
understanding of the pathophysiological
processes that underlie many complex
diseases, such as cancer, cardiovascular
disease, and infectious diseases. This
increased understanding has provided
further impetus for new therapeutic
approaches that rely primarily or
exclusively on combinations of drugs
directed at multiple therapeutic targets
to improve treatment response and
minimize development of resistance. In
settings in which combination therapy
provides significant therapeutic
advantages, there is growing interest in
the development of combinations of
investigational drugs not previously
developed for any purpose.
Because the existing developmental
and regulatory paradigm focuses
primarily on assessment of the
effectiveness and safety of a single new
investigational drug acting alone, or in
combination with an approved drug,
FDA believes guidance is needed to
assist sponsors in the codevelopment of
two or more unmarketed drugs. This
guidance is intended to describe a highlevel, generally applicable approach to
codevelopment of two or more
unmarketed drugs. It describes the
criteria for determining when
codevelopment is an appropriate option,
makes recommendations about
nonclinical and clinical development
strategies, and addresses certain
regulatory process issues. The guidance
does not apply to vaccines, gene or
cellular therapies, or blood products.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
78259
The draft guidance, when finalized, will
represent the Agency’s current thinking
on companion diagnostic devices. It
does not create or confer any rights for
or on any person and does not operate
to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet
may obtain the document at either http:
//www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
Dated: December 9, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–31426 Filed 12–14–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0618]
Statement of Organization, Functions
and Delegations of Authority
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) has reorganized
its Center for Tobacco Products (CTP) by
establishing two new offices: Office of
Health Communication and Education
and the Office of Compliance and
Enforcement. In addition, CTP has made
improvements to the current offices’
functional statements. This
organizational change is intended to fill
the gaps in the current CTP structure
and clarify major responsibilities
designed for long-term success in
administering the Family Smoking
Prevention and Tobacco Control Act.
SUMMARY:
E:\FR\FM\15DEN1.SGM
15DEN1
78260
Federal Register / Vol. 75, No. 240 / Wednesday, December 15, 2010 / Notices
Erik
Mettler, Office of Management; or
Sharon Chartos, Office of Management,
Center for Tobacco Products, Food and
Drug Administration, 9200 Corporate
Blvd., Rockville, MD 20850, 301–796–
9200.
FOR FURTHER INFORMATION CONTACT:
I. Introduction
The Statement of Organization,
Functions and Delegations of Authority
for the Center for Tobacco Products (74
FR 41713, August 18, 2009) is amended
to reflect the restructuring of the Center
for Tobacco Products that was approved
by the Secretary of Health and Human
Services on November 15, 2010:
II. Organization
The Center for Tobacco Products is
headed by the Director and includes the
following organizational units:
hsrobinson on DSK69SOYB1PROD with NOTICES
Center For Tobacco Products (DI)
1. Oversees the implementation of the
Family Smoking Prevention and
Tobacco Control Act, which provides
FDA with several new authorities.
These include restricting the marketing
of tobacco products to minors; requiring
new warning labels for cigarettes and
smokeless tobacco products; prohibiting
marketing measures that are misleading
to consumers; establishing tobacco
product standards; requiring Good
Manufacturing Practice standards for
tobacco product manufacturing
facilities; requiring industry reporting of
tobacco product ingredient and
constituent data, including a description
of the nicotine content and delivery
mechanisms; educating the public and
regulated industry about various
provisions of the Family Smoking
Prevention and Tobacco Control Act;
and enforcement authorities including
but not limited to enabling FDA to act
quickly and effectively to remove
products that are in violation of the
statute.
2. Provides programmatic and policy
direction to appropriate Center and
Agency personnel on all matters related
to implementation of the Family
Smoking Prevention and Tobacco
Control Act and identifies critical public
health issues relating to tobacco product
use.
3. Establishes and maintains effective
relationships with senior FDA,
Department of Health and Human
Services (HHS), and Administration
officials, industry representatives,
Members of Congress, counterparts from
State, local, territorial, and tribal
governments, representatives from
academia and public health
organizations, and other key
VerDate Mar<15>2010
19:10 Dec 14, 2010
Jkt 223001
stakeholders on matters related to
tobacco products.
Office of the Center Director (DIA)
1. Provides vision, leadership, and
strategic direction for all Center
activities related to regulation of tobacco
products and implementation of the
Family Smoking Prevention and
Tobacco Control Act.
2. Provides vision, leadership, and
strategic direction for all Center
activities related to protecting the public
health and communicating about the
negative consequences of tobacco
product use.
3. Plans, administers, coordinates,
evaluates, and implements overall
Center scientific, legal, policy,
regulatory, compliance, public
education, and management programs,
policies, and plans.
4. Provides leadership and direction
for Center management, planning, and
evaluation systems to ensure optimum
utilization of personnel, budgetary and
financial resources, information
technology, professional development,
and facilities.
5. Establishes a program to maintain
the highest levels of scientific quality
and integrity for the Center.
6. Serves as the primary liaison and
spokesperson on tobacco products
regulation and the public health
consequences of tobacco products use
with FDA, HHS, Office of Management
and Budget (OMB), the White House,
Congress and the media, as well as with
a variety of stakeholders, including
regulated industry; tobacco control
advocacy organizations; scientific,
public health, and medical associations;
academia; and State, local, territorial,
and tribal governments.
7. Provides Center-wide program and
strategic planning, execution, and
support to Center leadership;
coordination, development, clearance,
and delivery of all Congressionally
mandated reports, studies, and analyses;
and also high quality briefing materials,
background information for meetings,
and speeches.
8. Provides correspondence control
for the Center and controls and
processes all public correspondence.
Develops and operates executive
correspondence tracking systems.
9. Manages the Center’s Freedom of
Information Act activities, coordinating
responses with other Center technical,
legal, regulatory, and policy units as
well as developing direct responses.
10. Manages the Center’s Ombudsman
program.
11. Manages the Center’s history
program and archives.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Office of Management (DIB)
1. Provides authoritative advice and
guidance to the Center Director on
management policies, guidelines, issues
and concerns that impact Center
programs and initiatives.
2. Provides leadership, guidance, and
direction regarding the development of
long-range strategic management plans,
operational plans, and systems for
Center activities. Directs technical
support staff in providing essential
management services and other critical
support functions.
3. Provides leadership and guidance
as primary liaison with the FDA Office
of Management to ensure provision of a
broad range of essential technical
support services.
4. Provides leadership and effective
coordination as the primary Center
liaison and expert with the Office of
Information Management for provision
and continuous improvement of
information technology services to
include networking, scientific
computing software engineering,
systems, and telecommunications.
5. Designs and develops performance
management systems and operational/
business process plans.
6. Analyzes management performance
trends, FDA cost structure, and use of
program resources.
7. Directs a variety of short-range and
long-range special projects or
assignments of substantial significance
to the Center.
8. Administers and executes the
Center management and fiscal planning
and performance activities, budget
formulation and execution, payroll,
accounting, and property management
functions.
9. Analyzes, formulates, and develops
the annual budget for the Center in
accordance with FDA, HHS, OMB, and
Congressional guidelines. Provides
oversight and ensures compliance with
all regulations governing financial
processes as outlined in FDA, HHS,
OMB, and U.S. Government
Accountability Office policies. Manages
FDA, HHS, OMB, and Congressional
inquiries regarding budget formulation
and execution and required quarterly
reports to Congressional Appropriations
Committees.
10. Develops, maintains, monitors,
analyzes, and reports data to Center
management and program officials on
the Center’s budget/planning resource
monitoring and evaluations systems.
11. Provides leadership within the
Center to ensure compliance with
statutes, executive orders, and
administrative directives, such as the
Chief Financial Officer Act and the
E:\FR\FM\15DEN1.SGM
15DEN1
Federal Register / Vol. 75, No. 240 / Wednesday, December 15, 2010 / Notices
hsrobinson on DSK69SOYB1PROD with NOTICES
Federal Financial Managers’ Financial
Integrity Act.
12. Serves as the liaison between the
CTP and the Bethesda Field Office,
Atlanta Field Office, and/or Office of
Management Programs on all personnel
issues including, but not limited to,
Human Capital Resources, appointment
mechanisms, recruitment flexibilities,
Senior Executive Service (SES)
appointments, Title 42 appointments,
retention flexibilities, and position
management. Manages the Center’s
Performance Management program and
the Center’s Awards program.
13. Manages, tracks, and maintains
the Center’s regulatory submissions in
accordance with FDA’s records
retention policies.
14. Receives, tracks, and stores all of
Center’s regulatory submissions.
15. Manages, conducts, and analyzes
studies designed to improve Center
processes and resource utilization and
support requirements.
16. Manages facility-related activities
for the Center including leases, space
needs, maintenance, and development
of architectural plans for move to FDA’s
White Oak campus.
17. Manages the Center’s employee
training and development activities,
including individual employee
development plans. Manages the
Center’s regulatory science fellowship
program and other academic-based
fellowship programs.
Office of Policy (DIC)
1. Advises the Center Director and
other key Agency officials on public
health, scientific, and regulatory policy
development at the Center.
2. Develops and evaluates Centerwide priorities and policies, assuring
FDA’s statutory public health goals and
policy needs are integrated into
initiatives across science, regulations,
compliance, public education, and
management programs across the
Center.
3. Ensures that Center policy
decisions are consensus-based and
informed, when relevant and
appropriate, through communications
with stakeholders in CTP, FDA, the
Centers for Disease Control and
Prevention, National Institutes for
Health, HHS, and other government and
relevant stakeholders and private
agencies.
4. Monitors, coordinates, and advises
the Center Director on policy involving
sensitive, controversial, and complex
issues related to Center activities that
may involve precedent-setting matters
or issues of particular concern to the
Center Director or FDA Commissioner of
Food and Drugs.
VerDate Mar<15>2010
19:10 Dec 14, 2010
Jkt 223001
5. Analyzes and evaluates the impact
and effectiveness of the Center’s overall
impact on public health.
6. Oversees public health policy and
analytics; coordinates and conducts
contingency analyses; manages special
projects that require quick reaction/
problem solving and planning; and
develops and oversees the Center’s
approach to evolving issues in tobacco
product regulation and control, such as
impact on population health,
development of policy aspects of
tobacco product standards, modified
risk products, substantial equivalence,
and marketing and advertising.
7. Provides economic and modeling
analyses on policy options as required.
8. Provides authoritative policy
advice, guidance, assistance,
interpretations, and recommendations
to CTP, FDA, HHS officials, and
scientific and professional personnel,
intra-governmental counterparts (State,
territorial and tribal officials).
9. Prepares and reviews legislative
proposals, Congressional testimony; and
materials related to implementing,
amending, or modifying the Family
Smoking Prevention and Tobacco
Control Act, FDA laws, and regulations
in collaboration with the Office of the
Commissioner, Office of Legislation.
10. Provides advice and analysis for
international tobacco control policies
and acts as the Center’s liaison with
international stakeholders, including
foreign governments.
11. Advises external stakeholders,
including large and small tobacco
manufacturers, tobacco control
advocacy groups, medical and
professional trade associations, State,
territorial, local, and tribal governments,
and others concerning the policy
implications of the law and regulations.
12. Manages the Center’s small
business assistance activities.
Office of Regulations (DID)
1. Provides Center’s oversight and
leadership in, and coordinates the
development of regulations, policies,
procedures, and guidance related to the
regulation of tobacco products.
2. Reviews and clears draft
regulations developed by the Center,
other FDA Centers, and other agencies.
3. Provides Center-level leadership
and coordination for briefings within
FDA, and with HHS, OMB, and other
Federal agencies related to regulations
and guidance documents.
4. Serves as the Center’s focal point
for developing and maintaining
communications, policies, and programs
with regard to regulations development,
review, clearance, and publication.
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
78261
5. Serves as the Center’s primary
liaison with the FDA’s Office of Chief
Counsel and the HHS Office of General
Counsel; and provides support for legal
defense in litigation.
6. Manages the development and
implementation of plans for the Center’s
regulation development activities.
7. Provides technical assistance on the
development of legislative proposals
related to FDA responsibilities of the
Family Smoking Prevention and
Tobacco Control Act.
8. Manages the citizens’ petition
process on behalf of the Center.
9. Supports the Center in its
regulatory litigation activities.
Office of Science (DIE)
1. Conducts scientific research and
reviews programs to support the
Center’s goals for implementing the
Family Smoking Prevention and
Tobacco Control Act, as part of a
comprehensive effort to reduce the toll
of disease, disability, and death caused
by tobacco products.
2. Serves as the focal point for overall
management of Center activities related
to science priorities and resources.
Advises and assists the Center Director,
FDA Commissioner of Food and Drugs,
and other key officials on scientific
issues that have an impact on public
health, policy, direction, and long-range
goals, and on the functions, capabilities,
and management of scientific research
facilities; and participates with other
Agency components in planning such
facilities.
3. Coordinates the Tobacco Products
Scientific Advisory Committee which
advises the Center Director, FDA
Commissioner of Food and Drugs, HHS
Secretary of Health and Human
Services, and other key officials on
certain issues related to the public
health impact of tobacco products.
4. Organizes, plans, directs, and
conducts research related to the
development, manufacture, testing,
labeling, and marketing of tobacco
products in order to develop and
maintain a scientific base for
establishing policies, tobacco product
standards, and test methods appropriate
for the protection of public health.
5. Plans, directs, and conducts
epidemiological research regarding the
initiation, use, and cessation of tobacco
products and the impact on the public
health.
6. Coordinates targeted research to
address Center priorities in
collaboration with leading scientists in
other segments of FDA, other Federal
agencies, and the scientific community
at large.
E:\FR\FM\15DEN1.SGM
15DEN1
hsrobinson on DSK69SOYB1PROD with NOTICES
78262
Federal Register / Vol. 75, No. 240 / Wednesday, December 15, 2010 / Notices
7. Plans, directs, and conducts
research related to behavioral science,
including consumer behavior and
consumer perception of risks of harm
from tobacco products.
8. Establishes and publishes a list of
harmful and potentially harmful
constituents in each regulated tobacco
product.
9. Develops policies and procedures
governing the submission and review of
ingredient and constituent information
for regulated tobacco products and
oversees their implementation.
10. Develops and implements policies
and procedures governing the
submission and review of applications
and postmarketing surveillance studies
for modified-risk tobacco products.
11. Develops and implements policies
and procedures governing the
submission and premarket review of
reports of substantially equivalent
tobacco products and applications for
new tobacco products.
12. Develops and implements policies
and procedures governing submission
and review of information regarding
investigational tobacco products.
13. Develops, maintains, monitors,
and analyzes policies, programs, and
databases of adverse reactions to
tobacco products.
14. Reviews, evaluates, and takes
appropriate action on recommendations
concerning denial or withdrawal of
marketing and modified-risk
authorizations for tobacco products.
15. Develops, in coordination with
other Center offices, standards for Good
Manufacturing Practices regarding
methods, facilities, and controls for
manufacturing, testing, and storage of
tobacco products.
16. Participates, in coordination with
other Agency components, in
inspections of manufacturing facilities
for compliance with applicable
manufacturing and tobacco product
standards.
17. Represents the Center in
interactions with other government
agencies, State and local governments,
industry, academia, consumer
organizations, Congress, national and
international organizations, and the
scientific community on tobacco science
and regulation issues.
18. Coordinates and provides
guidance on science policy in program
areas that cross major Agency
component lines and on scientific
aspects of critical or controversial
issues, including Agency risk
assessment policies.
VerDate Mar<15>2010
19:10 Dec 14, 2010
Jkt 223001
Office of Health Communication and
Education (DIF)
1. Serves as a comprehensive health
communication enterprise developed as
a part of a comprehensive effort to
reduce the toll of disease, disability, and
death caused by tobacco products.
2. Develops, coordinates, and
evaluates public health communication
and education activities in support of
requirements of the Family Smoking
Prevention and Tobacco Control Act.
3. Serves as the central point for
communication about the Center’s
activities, campaigns, and key messages,
including executing programs and
implementing strategies about the
regulation of tobacco products and the
health risks associated with tobacco
product use.
4. Ensures consistent branding,
messaging, and strategic
communications for all Center public
education output.
5. Provides effective collaboration and
coordination with partners and
stakeholders on public health education
and communications programs.
6. Provides accurate and timely public
health information and education about
tobacco products regulation and the
requirements of the Family Smoking
Prevention and Tobacco Control Act.
7. Develops and manages
informational materials for health
professionals and consumers, including
Web pages and print media.
8. Manages Center’s Web sites
(Intranet and Internet).
9. Constructs risk communication
messages in support of the requirements
of the Family Smoking Prevention and
Tobacco Control Act, using appropriate
research methods.
10. Serves as the liaison between the
Center and its stakeholders on public
health education and communication
programs.
Office of Compliance and Enforcement
(DIG)
1. Advises the Center Director and
other Agency officials on legal,
administrative, and regulatory programs
and policies concerning Agency
compliance and enforcement
responsibilities relating to tobacco
products.
2. Coordinates, interprets, and
evaluates the Center’s overall
compliance and enforcement efforts.
3. Provides technical support and
guidance in the development and
review of standards, regulations, and
guidance related to compliance and
enforcement.
4. Develops, directs, coordinates,
evaluates, and monitors compliance and
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
enforcement programs covering
regulated industry.
5. Coordinates, develops, and directs
State compliance and enforcement
programs.
6. Provides training of Federal, State,
and territorial compliance personnel.
7. Conducts field tests and
inspections when necessary for
regulatory purposes and evaluates
regulated industry activities to assure
compliance with regulations.
8. Provides advice to Agency field
offices and commissioned officials, and
manages Center activities relating to
legal actions, case development, and
contested case assistance.
9. Designs, develops, and implements
Center programs to register tobacco
establishments and product lists.
10. Coordinates all field planning
activities and issues all field
assignments for the Center.
11. Advises actual or potential
manufacturers, distributors, retailers,
and importers concerning the
requirements of the law and regulations
related to compliance and enforcement.
III. Delegation of Authority
Pending further delegation, directives,
or orders by the Commissioner of Food
and Drugs, or the Director of Center for
Tobacco Products, all delegations and
redelegations of authority made to
officials and employees of affected
organizational components in effect
prior to this date will continue in effect
in them or their successors, provided
they are consistent with this
reorganization.
Dated: December 9, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–31383 Filed 12–14–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HOMELAND
SECURITY
Transportation Security Administration
Intent To Request Approval From OMB
of One New Public Collection of
Information: Airport Federalization
Transportation Security
Administration, DHS.
ACTION: 60-day notice.
AGENCY:
The Transportation Security
Administration (TSA) invites public
comment on a new Information
Collection Request (ICR) (abstracted
below) that we will submit to the Office
of Management and Budget (OMB) for
approval in compliance with the
Paperwork Reduction Act (PRA). The
SUMMARY:
E:\FR\FM\15DEN1.SGM
15DEN1
Agencies
[Federal Register Volume 75, Number 240 (Wednesday, December 15, 2010)]
[Notices]
[Pages 78259-78262]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-31383]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0618]
Statement of Organization, Functions and Delegations of Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has reorganized its
Center for Tobacco Products (CTP) by establishing two new offices:
Office of Health Communication and Education and the Office of
Compliance and Enforcement. In addition, CTP has made improvements to
the current offices' functional statements. This organizational change
is intended to fill the gaps in the current CTP structure and clarify
major responsibilities designed for long-term success in administering
the Family Smoking Prevention and Tobacco Control Act.
[[Page 78260]]
FOR FURTHER INFORMATION CONTACT: Erik Mettler, Office of Management; or
Sharon Chartos, Office of Management, Center for Tobacco Products, Food
and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850,
301-796-9200.
I. Introduction
The Statement of Organization, Functions and Delegations of
Authority for the Center for Tobacco Products (74 FR 41713, August 18,
2009) is amended to reflect the restructuring of the Center for Tobacco
Products that was approved by the Secretary of Health and Human
Services on November 15, 2010:
II. Organization
The Center for Tobacco Products is headed by the Director and
includes the following organizational units:
Center For Tobacco Products (DI)
1. Oversees the implementation of the Family Smoking Prevention and
Tobacco Control Act, which provides FDA with several new authorities.
These include restricting the marketing of tobacco products to minors;
requiring new warning labels for cigarettes and smokeless tobacco
products; prohibiting marketing measures that are misleading to
consumers; establishing tobacco product standards; requiring Good
Manufacturing Practice standards for tobacco product manufacturing
facilities; requiring industry reporting of tobacco product ingredient
and constituent data, including a description of the nicotine content
and delivery mechanisms; educating the public and regulated industry
about various provisions of the Family Smoking Prevention and Tobacco
Control Act; and enforcement authorities including but not limited to
enabling FDA to act quickly and effectively to remove products that are
in violation of the statute.
2. Provides programmatic and policy direction to appropriate Center
and Agency personnel on all matters related to implementation of the
Family Smoking Prevention and Tobacco Control Act and identifies
critical public health issues relating to tobacco product use.
3. Establishes and maintains effective relationships with senior
FDA, Department of Health and Human Services (HHS), and Administration
officials, industry representatives, Members of Congress, counterparts
from State, local, territorial, and tribal governments, representatives
from academia and public health organizations, and other key
stakeholders on matters related to tobacco products.
Office of the Center Director (DIA)
1. Provides vision, leadership, and strategic direction for all
Center activities related to regulation of tobacco products and
implementation of the Family Smoking Prevention and Tobacco Control
Act.
2. Provides vision, leadership, and strategic direction for all
Center activities related to protecting the public health and
communicating about the negative consequences of tobacco product use.
3. Plans, administers, coordinates, evaluates, and implements
overall Center scientific, legal, policy, regulatory, compliance,
public education, and management programs, policies, and plans.
4. Provides leadership and direction for Center management,
planning, and evaluation systems to ensure optimum utilization of
personnel, budgetary and financial resources, information technology,
professional development, and facilities.
5. Establishes a program to maintain the highest levels of
scientific quality and integrity for the Center.
6. Serves as the primary liaison and spokesperson on tobacco
products regulation and the public health consequences of tobacco
products use with FDA, HHS, Office of Management and Budget (OMB), the
White House, Congress and the media, as well as with a variety of
stakeholders, including regulated industry; tobacco control advocacy
organizations; scientific, public health, and medical associations;
academia; and State, local, territorial, and tribal governments.
7. Provides Center-wide program and strategic planning, execution,
and support to Center leadership; coordination, development, clearance,
and delivery of all Congressionally mandated reports, studies, and
analyses; and also high quality briefing materials, background
information for meetings, and speeches.
8. Provides correspondence control for the Center and controls and
processes all public correspondence. Develops and operates executive
correspondence tracking systems.
9. Manages the Center's Freedom of Information Act activities,
coordinating responses with other Center technical, legal, regulatory,
and policy units as well as developing direct responses.
10. Manages the Center's Ombudsman program.
11. Manages the Center's history program and archives.
Office of Management (DIB)
1. Provides authoritative advice and guidance to the Center
Director on management policies, guidelines, issues and concerns that
impact Center programs and initiatives.
2. Provides leadership, guidance, and direction regarding the
development of long-range strategic management plans, operational
plans, and systems for Center activities. Directs technical support
staff in providing essential management services and other critical
support functions.
3. Provides leadership and guidance as primary liaison with the FDA
Office of Management to ensure provision of a broad range of essential
technical support services.
4. Provides leadership and effective coordination as the primary
Center liaison and expert with the Office of Information Management for
provision and continuous improvement of information technology services
to include networking, scientific computing software engineering,
systems, and telecommunications.
5. Designs and develops performance management systems and
operational/business process plans.
6. Analyzes management performance trends, FDA cost structure, and
use of program resources.
7. Directs a variety of short-range and long-range special projects
or assignments of substantial significance to the Center.
8. Administers and executes the Center management and fiscal
planning and performance activities, budget formulation and execution,
payroll, accounting, and property management functions.
9. Analyzes, formulates, and develops the annual budget for the
Center in accordance with FDA, HHS, OMB, and Congressional guidelines.
Provides oversight and ensures compliance with all regulations
governing financial processes as outlined in FDA, HHS, OMB, and U.S.
Government Accountability Office policies. Manages FDA, HHS, OMB, and
Congressional inquiries regarding budget formulation and execution and
required quarterly reports to Congressional Appropriations Committees.
10. Develops, maintains, monitors, analyzes, and reports data to
Center management and program officials on the Center's budget/planning
resource monitoring and evaluations systems.
11. Provides leadership within the Center to ensure compliance with
statutes, executive orders, and administrative directives, such as the
Chief Financial Officer Act and the
[[Page 78261]]
Federal Financial Managers' Financial Integrity Act.
12. Serves as the liaison between the CTP and the Bethesda Field
Office, Atlanta Field Office, and/or Office of Management Programs on
all personnel issues including, but not limited to, Human Capital
Resources, appointment mechanisms, recruitment flexibilities, Senior
Executive Service (SES) appointments, Title 42 appointments, retention
flexibilities, and position management. Manages the Center's
Performance Management program and the Center's Awards program.
13. Manages, tracks, and maintains the Center's regulatory
submissions in accordance with FDA's records retention policies.
14. Receives, tracks, and stores all of Center's regulatory
submissions.
15. Manages, conducts, and analyzes studies designed to improve
Center processes and resource utilization and support requirements.
16. Manages facility-related activities for the Center including
leases, space needs, maintenance, and development of architectural
plans for move to FDA's White Oak campus.
17. Manages the Center's employee training and development
activities, including individual employee development plans. Manages
the Center's regulatory science fellowship program and other academic-
based fellowship programs.
Office of Policy (DIC)
1. Advises the Center Director and other key Agency officials on
public health, scientific, and regulatory policy development at the
Center.
2. Develops and evaluates Center-wide priorities and policies,
assuring FDA's statutory public health goals and policy needs are
integrated into initiatives across science, regulations, compliance,
public education, and management programs across the Center.
3. Ensures that Center policy decisions are consensus-based and
informed, when relevant and appropriate, through communications with
stakeholders in CTP, FDA, the Centers for Disease Control and
Prevention, National Institutes for Health, HHS, and other government
and relevant stakeholders and private agencies.
4. Monitors, coordinates, and advises the Center Director on policy
involving sensitive, controversial, and complex issues related to
Center activities that may involve precedent-setting matters or issues
of particular concern to the Center Director or FDA Commissioner of
Food and Drugs.
5. Analyzes and evaluates the impact and effectiveness of the
Center's overall impact on public health.
6. Oversees public health policy and analytics; coordinates and
conducts contingency analyses; manages special projects that require
quick reaction/problem solving and planning; and develops and oversees
the Center's approach to evolving issues in tobacco product regulation
and control, such as impact on population health, development of policy
aspects of tobacco product standards, modified risk products,
substantial equivalence, and marketing and advertising.
7. Provides economic and modeling analyses on policy options as
required.
8. Provides authoritative policy advice, guidance, assistance,
interpretations, and recommendations to CTP, FDA, HHS officials, and
scientific and professional personnel, intra-governmental counterparts
(State, territorial and tribal officials).
9. Prepares and reviews legislative proposals, Congressional
testimony; and materials related to implementing, amending, or
modifying the Family Smoking Prevention and Tobacco Control Act, FDA
laws, and regulations in collaboration with the Office of the
Commissioner, Office of Legislation.
10. Provides advice and analysis for international tobacco control
policies and acts as the Center's liaison with international
stakeholders, including foreign governments.
11. Advises external stakeholders, including large and small
tobacco manufacturers, tobacco control advocacy groups, medical and
professional trade associations, State, territorial, local, and tribal
governments, and others concerning the policy implications of the law
and regulations.
12. Manages the Center's small business assistance activities.
Office of Regulations (DID)
1. Provides Center's oversight and leadership in, and coordinates
the development of regulations, policies, procedures, and guidance
related to the regulation of tobacco products.
2. Reviews and clears draft regulations developed by the Center,
other FDA Centers, and other agencies.
3. Provides Center-level leadership and coordination for briefings
within FDA, and with HHS, OMB, and other Federal agencies related to
regulations and guidance documents.
4. Serves as the Center's focal point for developing and
maintaining communications, policies, and programs with regard to
regulations development, review, clearance, and publication.
5. Serves as the Center's primary liaison with the FDA's Office of
Chief Counsel and the HHS Office of General Counsel; and provides
support for legal defense in litigation.
6. Manages the development and implementation of plans for the
Center's regulation development activities.
7. Provides technical assistance on the development of legislative
proposals related to FDA responsibilities of the Family Smoking
Prevention and Tobacco Control Act.
8. Manages the citizens' petition process on behalf of the Center.
9. Supports the Center in its regulatory litigation activities.
Office of Science (DIE)
1. Conducts scientific research and reviews programs to support the
Center's goals for implementing the Family Smoking Prevention and
Tobacco Control Act, as part of a comprehensive effort to reduce the
toll of disease, disability, and death caused by tobacco products.
2. Serves as the focal point for overall management of Center
activities related to science priorities and resources. Advises and
assists the Center Director, FDA Commissioner of Food and Drugs, and
other key officials on scientific issues that have an impact on public
health, policy, direction, and long-range goals, and on the functions,
capabilities, and management of scientific research facilities; and
participates with other Agency components in planning such facilities.
3. Coordinates the Tobacco Products Scientific Advisory Committee
which advises the Center Director, FDA Commissioner of Food and Drugs,
HHS Secretary of Health and Human Services, and other key officials on
certain issues related to the public health impact of tobacco products.
4. Organizes, plans, directs, and conducts research related to the
development, manufacture, testing, labeling, and marketing of tobacco
products in order to develop and maintain a scientific base for
establishing policies, tobacco product standards, and test methods
appropriate for the protection of public health.
5. Plans, directs, and conducts epidemiological research regarding
the initiation, use, and cessation of tobacco products and the impact
on the public health.
6. Coordinates targeted research to address Center priorities in
collaboration with leading scientists in other segments of FDA, other
Federal agencies, and the scientific community at large.
[[Page 78262]]
7. Plans, directs, and conducts research related to behavioral
science, including consumer behavior and consumer perception of risks
of harm from tobacco products.
8. Establishes and publishes a list of harmful and potentially
harmful constituents in each regulated tobacco product.
9. Develops policies and procedures governing the submission and
review of ingredient and constituent information for regulated tobacco
products and oversees their implementation.
10. Develops and implements policies and procedures governing the
submission and review of applications and postmarketing surveillance
studies for modified-risk tobacco products.
11. Develops and implements policies and procedures governing the
submission and premarket review of reports of substantially equivalent
tobacco products and applications for new tobacco products.
12. Develops and implements policies and procedures governing
submission and review of information regarding investigational tobacco
products.
13. Develops, maintains, monitors, and analyzes policies, programs,
and databases of adverse reactions to tobacco products.
14. Reviews, evaluates, and takes appropriate action on
recommendations concerning denial or withdrawal of marketing and
modified-risk authorizations for tobacco products.
15. Develops, in coordination with other Center offices, standards
for Good Manufacturing Practices regarding methods, facilities, and
controls for manufacturing, testing, and storage of tobacco products.
16. Participates, in coordination with other Agency components, in
inspections of manufacturing facilities for compliance with applicable
manufacturing and tobacco product standards.
17. Represents the Center in interactions with other government
agencies, State and local governments, industry, academia, consumer
organizations, Congress, national and international organizations, and
the scientific community on tobacco science and regulation issues.
18. Coordinates and provides guidance on science policy in program
areas that cross major Agency component lines and on scientific aspects
of critical or controversial issues, including Agency risk assessment
policies.
Office of Health Communication and Education (DIF)
1. Serves as a comprehensive health communication enterprise
developed as a part of a comprehensive effort to reduce the toll of
disease, disability, and death caused by tobacco products.
2. Develops, coordinates, and evaluates public health communication
and education activities in support of requirements of the Family
Smoking Prevention and Tobacco Control Act.
3. Serves as the central point for communication about the Center's
activities, campaigns, and key messages, including executing programs
and implementing strategies about the regulation of tobacco products
and the health risks associated with tobacco product use.
4. Ensures consistent branding, messaging, and strategic
communications for all Center public education output.
5. Provides effective collaboration and coordination with partners
and stakeholders on public health education and communications
programs.
6. Provides accurate and timely public health information and
education about tobacco products regulation and the requirements of the
Family Smoking Prevention and Tobacco Control Act.
7. Develops and manages informational materials for health
professionals and consumers, including Web pages and print media.
8. Manages Center's Web sites (Intranet and Internet).
9. Constructs risk communication messages in support of the
requirements of the Family Smoking Prevention and Tobacco Control Act,
using appropriate research methods.
10. Serves as the liaison between the Center and its stakeholders
on public health education and communication programs.
Office of Compliance and Enforcement (DIG)
1. Advises the Center Director and other Agency officials on legal,
administrative, and regulatory programs and policies concerning Agency
compliance and enforcement responsibilities relating to tobacco
products.
2. Coordinates, interprets, and evaluates the Center's overall
compliance and enforcement efforts.
3. Provides technical support and guidance in the development and
review of standards, regulations, and guidance related to compliance
and enforcement.
4. Develops, directs, coordinates, evaluates, and monitors
compliance and enforcement programs covering regulated industry.
5. Coordinates, develops, and directs State compliance and
enforcement programs.
6. Provides training of Federal, State, and territorial compliance
personnel.
7. Conducts field tests and inspections when necessary for
regulatory purposes and evaluates regulated industry activities to
assure compliance with regulations.
8. Provides advice to Agency field offices and commissioned
officials, and manages Center activities relating to legal actions,
case development, and contested case assistance.
9. Designs, develops, and implements Center programs to register
tobacco establishments and product lists.
10. Coordinates all field planning activities and issues all field
assignments for the Center.
11. Advises actual or potential manufacturers, distributors,
retailers, and importers concerning the requirements of the law and
regulations related to compliance and enforcement.
III. Delegation of Authority
Pending further delegation, directives, or orders by the
Commissioner of Food and Drugs, or the Director of Center for Tobacco
Products, all delegations and redelegations of authority made to
officials and employees of affected organizational components in effect
prior to this date will continue in effect in them or their successors,
provided they are consistent with this reorganization.
Dated: December 9, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-31383 Filed 12-14-10; 8:45 am]
BILLING CODE 4160-01-P